{"id":379055,"date":"2020-11-11T16:33:17","date_gmt":"2020-11-11T21:33:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379055"},"modified":"2020-11-11T16:33:17","modified_gmt":"2020-11-11T21:33:17","slug":"protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/","title":{"rendered":"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEWARK, Calif.<\/span>, Nov. 11, 2020<\/span> \/PRNewswire\/ —\u00a0Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel<\/span>, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual 2020 London Healthcare Conference.<\/p>\n

Presentation details:
Date: Tuesday, Nov. 17, 2020<\/span>
Time: 5:35 p.m. GMT<\/span> (12:35 p.m. EST<\/span>)<\/p>\n

A live and archived webcast of the event will be available at https:\/\/wsw.com\/webcast\/jeff141\/ptgx\/1873875<\/a>\u00a0and in the Investors section of the Protagonist Therapeutics website at http:\/\/investors.protagonist-inc.com\/<\/a>. <\/p>\n

\n About Protagonist Therapeutics, Inc.<\/b>\n <\/p>\n

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn’s disease as the initial indication. In addition to PTG-200, two oral peptide interleukin-23 receptor antagonist candidates from a collaboration with Janssen Biotech, Inc., are in development and have been selected for advancement into clinical studies. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.<\/p>\n

Protagonist is headquartered in Newark, California<\/span>. For further information, please visit http:\/\/www.protagonist-inc.com<\/a>. <\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference-301171288.html<\/a><\/p>\n

SOURCE Protagonist Therapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEWARK, Calif., Nov. 11, 2020 \/PRNewswire\/ —\u00a0Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual 2020 London Healthcare Conference. Presentation details: Date: Tuesday, Nov. 17, 2020Time: 5:35 p.m. GMT (12:35 p.m. EST) A live and archived webcast of the event will be available at https:\/\/wsw.com\/webcast\/jeff141\/ptgx\/1873875\u00a0and in the Investors section of the Protagonist Therapeutics website at http:\/\/investors.protagonist-inc.com\/. About Protagonist Therapeutics, Inc. Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage … <\/p>\n

Continue reading “Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379055","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nProtagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEWARK, Calif., Nov. 11, 2020 \/PRNewswire\/ —\u00a0Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual 2020 London Healthcare Conference. Presentation details: Date: Tuesday, Nov. 17, 2020Time: 5:35 p.m. GMT (12:35 p.m. EST) A live and archived webcast of the event will be available at https:\/\/wsw.com\/webcast\/jeff141\/ptgx\/1873875\u00a0and in the Investors section of the Protagonist Therapeutics website at http:\/\/investors.protagonist-inc.com\/. About Protagonist Therapeutics, Inc. Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage … Continue reading "Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-11T21:33:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF88643&sd=2020-11-11\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference\",\"datePublished\":\"2020-11-11T21:33:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/\"},\"wordCount\":274,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=SF88643&sd=2020-11-11\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/\",\"name\":\"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=SF88643&sd=2020-11-11\",\"datePublished\":\"2020-11-11T21:33:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=SF88643&sd=2020-11-11\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=SF88643&sd=2020-11-11\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference - Market Newsdesk","og_description":"PR Newswire NEWARK, Calif., Nov. 11, 2020 \/PRNewswire\/ —\u00a0Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual 2020 London Healthcare Conference. Presentation details: Date: Tuesday, Nov. 17, 2020Time: 5:35 p.m. GMT (12:35 p.m. EST) A live and archived webcast of the event will be available at https:\/\/wsw.com\/webcast\/jeff141\/ptgx\/1873875\u00a0and in the Investors section of the Protagonist Therapeutics website at http:\/\/investors.protagonist-inc.com\/. About Protagonist Therapeutics, Inc. Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage … Continue reading \"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-11T21:33:17+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF88643&sd=2020-11-11","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference","datePublished":"2020-11-11T21:33:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/"},"wordCount":274,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF88643&sd=2020-11-11","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/","name":"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF88643&sd=2020-11-11","datePublished":"2020-11-11T21:33:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF88643&sd=2020-11-11","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF88643&sd=2020-11-11"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protagonist-therapeutics-to-participate-in-the-jefferies-virtual-2020-london-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379055"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379055\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}